Literature DB >> 24630337

In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.

Michele Senni1, Antonello Gavazzi1, Fabrizio Oliva2, Andrea Mortara3, Renato Urso4, Massimo Pozzoli5, Marco Metra6, Donata Lucci4, Lucio Gonzini4, Vincenzo Cirrincione7, Laura Montagna8, Andrea Di Lenarda9, Aldo P Maggioni10, Luigi Tavazzi5.   

Abstract

BACKGROUND: To investigate the outcomes of hospitalized patients with both de-novo and worsening heart failure (HF) with preserved left ventricular ejection fraction (LVEF) (HFpEF) (LVEF ≥ 50%), compared to those with reduced LVEF (HFrEF). METHODS AND
RESULTS: We studied 1669 patients (22.6% HFpEF) hospitalized for acute HF in the prospective multi-center nationwide Italian Network on Heart Failure (IN-HF) Outcome Registry. In all patients LVEF was assessed during hospitalization. De-novo HF presentations constituted 49.6% of HFpEF and 43.1% of HFrEF hospitalizations. All-cause mortality during hospitalization was lower in HFpEF than HFrEF (2.9% vs 6.5%, p=0.01), but this mortality difference was not significant at 1 year (19.6% vs 24.4%, p=0.06), even after adjusting for clinical covariates. Similarly, there were no differences in 1-year mortality between HFpEF and HFrEF when compared by cause of death (cardiovascular vs non-cardiovascular) or mode of presentation (worsening HF vs de novo). Rehospitalization rates (all-cause, non-cardiovascular, cardiovascular, HF-related) at 90 days and 1 year were also similar. Mode of presentation influenced rehospitalizations in HFpEF, where those presenting with worsening HFpEF had higher all-cause (36.8% vs 21.6%, p=0.001), cardiovascular (28.1% vs 14.9%, p=0.002), and HF-related (21.1% vs 7.7%, p=0.0003) rehospitalization rates at 1 year compared to those with de novo presentations.
CONCLUSIONS: Outcomes at 1 year following hospitalization for HFpEF are as poor as that of HFrEF. A prior history of HF decompensation or hospitalization identifies patients with HFpEF at particularly high risk of recurrent events. These findings may have implications for clinical practice, quality and process improvements and trial design.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute heart failure; Heart failure with preserved ejection fraction; Prognosis; Registry

Mesh:

Substances:

Year:  2014        PMID: 24630337     DOI: 10.1016/j.ijcard.2014.02.018

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  29 in total

1.  Recurrent Acute Decompensated Heart Failure Admissions for Patients With Reduced Versus Preserved Ejection Fraction (from the Atherosclerosis Risk in Communities Study).

Authors:  Melissa C Caughey; Carla A Sueta; Sally C Stearns; Amil M Shah; Wayne D Rosamond; Patricia P Chang
Journal:  Am J Cardiol       Date:  2018-03-28       Impact factor: 2.778

2.  The Mechanism of Action of LCZ696.

Authors:  Juan Tamargo Menendez
Journal:  Card Fail Rev       Date:  2016-05

3.  Creation and validation of the acute heart failure risk score: AHFRS.

Authors:  Susana Garcia-Gutierrez; José Maria Quintana; Ane Antón-Ladislao; Maria Soledad Gallardo; Esther Pulido; Irene Rilo; Elena Zubillaga; Miren Morillas; José Juan Onaindia; Nekane Murga; Ricardo Palenzuela; José González Ruiz
Journal:  Intern Emerg Med       Date:  2016-10-11       Impact factor: 3.397

4.  One-Year Outcomes of Acute Decompensated Systolic Heart Failure in Taiwan: Lessons from TSOC-HFrEF Registry.

Authors:  Hung-Yu Chang; Chun-Chieh Wang; Yen-Wen Wu; Pao-Hsien Chu; Chih-Cheng Wu; Chih-Hsin Hsu; Ming-Shien Wen; Wen-Chol Voon; Wei-Shiang Lin; Jin-Long Huang; Shyh-Ming Chen; Ning-I Yang; Heng-Chia Chang; Kuan-Cheng Chang; Shih-Hsien Sung; Kou-Gi Shyu; Jiunn-Lee Lin; Guang-Yuan Mar; Kuei-Chuan Chan; Jen-Yuan Kuo; Ji-Hung Wang; Zhih-Cherng Chen; Wei-Kung Tseng; Wen-Jin Cherng; Wei-Hsian Yin
Journal:  Acta Cardiol Sin       Date:  2017-03       Impact factor: 2.672

5.  The Management of Heart Failure with Preserved Ejection Fraction.

Authors:  Andrew Js Coats; Louise G Shewan
Journal:  Card Fail Rev       Date:  2015-04

Review 6.  Epidemiology of heart failure with preserved ejection fraction.

Authors:  Shannon M Dunlay; Véronique L Roger; Margaret M Redfield
Journal:  Nat Rev Cardiol       Date:  2017-05-11       Impact factor: 32.419

7.  Medication Adherence Mediates the Relationship Between Heart Failure Symptoms and Cardiac Event-Free Survival in Patients With Heart Failure.

Authors:  Jia-Rong Wu; Debra K Moser
Journal:  J Cardiovasc Nurs       Date:  2018 Jan/Feb       Impact factor: 2.083

Review 8.  Addressing the Heterogeneity of Heart Failure in Future Randomized Trials.

Authors:  Annamaria Iorio; Andrea Pozzi; Michele Senni
Journal:  Curr Heart Fail Rep       Date:  2017-06

Review 9.  New medical therapies for heart failure.

Authors:  Thomas G von Lueder; Henry Krum
Journal:  Nat Rev Cardiol       Date:  2015-09-29       Impact factor: 32.419

Review 10.  New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.

Authors:  Michele Senni; Walter J Paulus; Antonello Gavazzi; Alan G Fraser; Javier Díez; Scott D Solomon; Otto A Smiseth; Marco Guazzi; Carolyn S P Lam; Aldo P Maggioni; Carsten Tschöpe; Marco Metra; Scott L Hummel; Frank Edelmann; Giuseppe Ambrosio; Andrew J Stewart Coats; Gerasimos S Filippatos; Mihai Gheorghiade; Stefan D Anker; Daniel Levy; Marc A Pfeffer; Wendy Gattis Stough; Burkert M Pieske
Journal:  Eur Heart J       Date:  2014-08-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.